• Data
    • Overview
    • Clinical notes
    • Images
    • Mother-child
    • Oncology
    • Regulatory grade
    • Truveta Language Model
    • Truveta Studio
  • Genomics
  • Solutions
    • Medical devices
    • Life science
    • Public health
    • Healthcare
  • Research
  • Resources
  • About
    • Blog
    • Members
    • Leadership
    • Events & webinars
    • Newsroom
    • Careers
Get started
Sign in
A new Truveta study offers a hopeful sign: Syphilis incidence is down for the first time in decades

A new Truveta study offers a hopeful sign: Syphilis incidence is down for the first time in decades

by Ellie Lampton | Apr 15, 2025

Published in the American Journal of Preventative Medicine, the new study shows that for the first time since its peak in 2022, syphilis incidence has declined, with larger decreases for men and young adults. BELLEVUE, WA — April 9, 2025 — A new study published in the...
New Truveta data and capabilities help researchers accelerate scientifically rigorous research

New Truveta data and capabilities help researchers accelerate scientifically rigorous research

by Ellie Lampton | Mar 26, 2025

BELLEVUE, Wash. – March 26, 2025 – Today, Truveta announced that Truveta Data has expanded to include new administrative data to enable more comprehensive analyses of healthcare outcomes and patient journeys. The company also announced two new Truveta Studio...
Truveta Data expands beyond EHR data with linked closed claims for more than 200 million patients

Truveta Data expands beyond EHR data with linked closed claims for more than 200 million patients

by Ellie Lampton | Feb 13, 2025

Closed claims complete the longitudinal patient journey in Truveta Data, enabling regulatory grade safety and effectiveness studies, replacing clinical trials and registries BELLEVUE, Wash. – February 12, 2025 – Today, Truveta announced the expansion of Truveta Data...
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications

New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications

by Ellie Lampton | Jan 31, 2025

New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine at University of Pennsylvania BELLEVUE, Wash. – January 31, 2025 – Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor...
US health systems announce the Truveta Genome Project, creating the world’s largest and most diverse database to discover the science of humanity

US health systems announce the Truveta Genome Project, creating the world’s largest and most diverse database to discover the science of humanity

by Ellie Lampton | Jan 13, 2025

The Regeneron Genetics Center® will sequence up to ten million exomes, helping to accelerate drug discovery and transform patient care BELLEVUE, Wash. – January 13, 2025 – Today, leading US health systems, including Advocate Health, CommonSpirit Health, Henry Ford...
« Older Entries
Next Entries »

Share this


Recent posts

  • Rising use of GLP-1 medications among women with PCOS
  • Advancing biomedical AI: Enhancing BERT performance with LLM-generated annotations
  • Rate of cannabis-related ED visits around Thanksgiving (2021–2024)

Follow Truveta


Sign up for our newsletter

Ready to accelerate your research with representative, complete, and timely real-world data?

Truveta Data

Truveta Genome Project

Solutions

Research

Resources

Blog

Newsroom

Careers

Privacy notice

Contact us

© Truveta 2025

Our website uses cookies to ensure you have the best experience.